bioconjugation

CPhI Annual report forecasts CMOs to benefit from double digit approvals for ADCs in the next 3-years.

Novel payloads that target tumour-initiating cells on third generation ADCs could come to market in the next couple of years…

6 years ago

ADC Bio secures additional equity round investment

Wales, November 16, 2018: ADC Biotechnology (ADC Bio), announces that it has secured additional funding of £2.5 million from existing investors and…

6 years ago

‘Process innovation needs to be undertaken in early R&D – phase’ – predicts ADC Bio

Much needed more efficient manufacturing processes aren’t being completed by pharma for ADCs Wales, June 06, 2018: ADC Biotechnology (ADC Bio)…

6 years ago

ADC Bio secures £1.14m investment from Downing LLP to finance innovative bioconjugation and US expansion

Funding earmarked for US market penetration and development of groundbreaking upstream bioconjugation approach Wales, April 25, 2018: ADC Biotechnology (ADC Bio), announces that it has secured £1.14…

7 years ago